IGKV3D-20 and colorectal cancer: To investigate the in vivo anti‐tumor efficacy of the T96F‐mutated 1–2C‐2LL TCR engager, SW‐620‐HLA‐A11 cells stably expressing luciferase reporter (SW‐620‐HLA‐A11‐Luci) were subcutaneously (s.c.)implanted into NOD‐Prkdcem26Cd52Il2rgem26Cd22/NjuCrl (NCG) mice to establish a colorectal cancer model (Figure6A).[30] T cells from two donors were injected intravenously (i.v.)and three varied doses of TCR engager protein group (i.e., high, medium, and low doses with 10, 1, and 0.1 mg kg−1, respectively) were infused intraperitoneally (i.p.).